We have identified seven adenine nucleosides in urines of untreated adenosine deaminase (ADA) deficient patients, four of which (adenosine, 2'-deoxyadenosine, 1-methyladenosine and N6-methyladenosine) have been previously identified in urines of normals and/or ADA deficient patients. We confirm that ADA deficient patients excrete markedly increased amounts of 2'-deox- 
Inherited deficiency of the purine salvage enzyme, adenosine deaminase (ADA) results in a fatal infantile syndrome of severe combined immunodeficiency (ADA-SCID) (10, 15, 22, 25, 30) . Children with ADA deficiency have a profound defect in both cellular and humoral immunity, although in 10-15% of cases, the humoral defect may initially be less severe (22) . Affected children accumulate and/or excrete markedly increasd amounts of the ADA substrates, adenosine and 2'-deoxyadenosine, and the phosphorylated metabolite, deoxy ATP (dATP) (3, 5, 6, 9, 26-28, 32, 37, 41, 46, 50) .
Several pathophysiologic mechanisms have been proposed whereby accumulation of ADA substrates and their metabolites would result in immunodeficiency (5, 12, 15, 16, 21, 24, 40, 52) . The largest body of evidence supports the hypothesis that ~A T P , an inhibitor of ribonucleotide reductase, accumulates preferentially in, and prevents proliferation of, irnmunocompetent cells, primarily of the T cell class (2, 5, 6, 23, 38, 49, 54) . There is also in vivo and/or in vitro evidence for alternative mechanisms of toxicity, which would operate via depletion of pyrimidine pools, depletion of phosphoribosyl pyrophosphate and increases in cyclic AMP or S-adenosyl homocysteine (16, 21, 24, 40, 46, 55) . All of these mechanisms are dependent on accumulation of the substrates of ADA, adenosine and 2'-deoxyadenosine.
In addition to adenosine and 2'-deoxyadenosine, several other modified adenine nucleosides occur naturally (17, 19) and are substrates for ADA (1, 18, 43, 56) . Such naturally occurring modified adenine nucleosides might be expected to also accumulate in ADA deficient patients and possibly contribute to toxicity. We have, therefore, sought to determine if these modified adenine nucleosides are uniquely present, or present in increased amounts, in urine of ADA deficient patients. We have identified seven compounds in urines of ADA deficients, four of which (adenosine, 2'-deoxyadenosine, 1-methyladenosine and N"methy1adenosine) have been previously identified in urines of normals and/or ADA deficient patients (4,9,27,28,32,36,37,50). We have additionally found three other substrates of ADA not ~reviouslv detected in urine. These three compounds newly identified in urine are 2'-0-methyladenosine, N6,2'-0-dimethyladenosine and an as yet incompletely characterized modified adenine nucleoside, R-adenosine. Only ADA deficient patients excrete detectable amounts of 2'-0-methyladenosine, whereas both normal and ADA deficient children excrete N"2'-0-dimethyladenosine and the as yet unidentified ADA substrate R-adenosine. However, ADA deficient patients excrete increased amounts of R-adenosine.
MATERIALS AND METHODS

Materials.
Nucleosides were obtained from Sigma Co. (St. Louis, MO) or P&L (Milwaukee, WI). 2'-0-Methylinosine was generated by incubation of 2'-0-methyladenosine with calf intestinal ADA, type I from Sigma, and purified by high pressure liquid chromatography. 5'-Methylthioadenosine was generated by acid hydrolysis of ,S-adenosyl methionine (45) . 5'-deoxyadenosine and N~t h r e o n i n o~a r b o n~l adenosine were the generous gifts of respectively Dr. G. Elion and Dr. G.B. Chheda.
Anion exchange chromatography. Urines (stored frozen at -70 "C with 0.01% sodium azide) were chromatographed on an anion exchange column (Biorad AG I-X2, Richmond, CA) essentially as described by Kuttesch, et al. (32) except that four fractions were collected. Fraction 1, 1-6 ml; fraction 2, 7-3 1 ml; fraction 3, 32-52 ml and fraction 4, 53-73 ml (eluting after the addition of acid). Adenosine and 2'-deoxyadenosine eluted in fraction 2 and adenine in fraction 4, as previously described (32, 36) . The elution profiles of several authentic compounds, including modified adenine and guanine nucleosides and bases are shown in Figure I .
High pressure liquid chromarography (HPLC).
Urines (fractionated and unfractionated) were analyzed by HPLC on C 18 pBondapak columns (Waters Co., Milford, MA) by methods previously described (42) except that the gradient went from 0 to 40% methanol in 60 min. For further identification, peaks of interest were collected, dried under nitrogen, reconstituted with water, and reanalyzed following either treatment with ADA, acid hydrolysis or chromatography on Afigel601 (Biorad, Richmond, CA). UV ratios of compounds were determined by simultaneous monitoring at the two wavelengths specified. Retention times of relevant nucleosides and bases are listed in Table 1 .
Peak shifi and acid hydrolysis. Samples and authentic compounds were incubated with and without calf intestinal ADA (Sigma Type 1, St. Lfiuis, MO) (20,42) at 0.08, 1.5 and 15 IU/ml final concentration for 1-2 h at 37OC and then analyzed by HPLC ( Fig. 2 and Table 1 ). For hydrolysis of nucleosides to bases, peaks of interest were collected by HPLC, concentrated, reconstituted with H20 and an aliquot boiled for 30 min in 0.45 N perchloric acid and neutralized with KOH. The authentic compounds adenosine, 2'-deoxyadenosine, 2'-0-methyladenosine, N6-methyladenosine, I-methyladenosine, N6,N6,-dimethyladenosine and N6-isopentenyladenosine were hydrolyzed under the same conditions and the reaction products analyzed by HPLC. Nz-methylguanosine eluted in the last of the anion exchange fractions (Fig. I) and Table 1 . The authentic compounds were individually incubated with varying concentrations of adenosine deaminase and rechromatographed to determine elution times of the respective deamination products (Table I ). The tracing ( lowerpanel) demonstrates the results of treatment with adenosine deaminase of a mixture of the nucleosides present in the upper panel. Fig. 2B . HPLC of urine of an ADA deficient child before and after incubation with exogenous adenosine deaminase. The second anion exchange column fraction (see "Materials and Methods" and Fig. I ) from urine of an untreated ADA deficient child was concentrated and analyzed by HPLC, monitoring at 260 nm. The arrow indicates a 4-fold increase in sensitivity to a full scale of 0.02. Peaks coeluting with I-methyladenosine ( I Me Ar), adenosine (Ar), 2-deoxyadenosine (2' dAr), an unidentified modified adenine nucleoside (R-adenosine or " X ) , 2'-0-methyladenosine ( 7 -0 Me Ar), N"-methyladenosine (N%e Ar) and N"2'-0-dimethyladenosine (N"'0 Me Ar) (indicated in the upper panel) all disappeared after incubation with adenosine deaminase (lower panel). Peaks appeared after ADA treatment (lower panel) with the retention times of inosine (derived from deamination of adenosine and N"methy1adenosine). 2'-deoxyinosine (from 2'-deoxyadenosine) and I-methylinosine (from I-methyladenosine). (The presumed and authentic I-methyladenosine, N"2'-0-dimethyladenosine and Ntmethyladenosine peaks required approximately 200-and 20-fold higher concentrations of ADA than those used to completely deaminate adenosine or 2'-deoxyadenosine.) 2'-0-methylinosine (2'-0 Me In) (from 2'-0-methyladenosine and Nt2'-0-dimethyladenosine) and X-inosine elute shortly after I-methylinosine (see Table I ) and are "buried" in this chromatogram primarily because of the presence of an unidentified interfering peak eluting shortly after I-methylinosine, the high concentrations of I-methylinosine relative to 2'-0-methylinosine and R-inosine as well as the decreased sensitivity of detection of "inosine" as compared with "adenosine" compounds at 260 nm, the wavelength at which this chromatogram was monitored.
The chromatogram is only illustrative and the indicated identifications were based on studies where peaks were collected individually, concentrated and rechromatographed with and without incubation with ADA to determine coelution and authentic compounds, UV ratios and the retention times listed in Table I . For studies of 2'-0-methyladenosine and R-adenosine (peak "X"), the two compounds were also separated on Affigel 601 (see text).
c it was identified in the H P L C chromatogram both by coelution with the authentic compound and by "peak shift" using exogenous purine nucleoside phosphorylase in the phosphorolytic direction.
Affigel 601 columns. Affigel 601 (Biorad, Richmond, CA), a boronate gel that selectively binds cis-diol compounds a t high pH, was swollen and packed as directed and eluted as described for separation o f deoxy ribonucleotides and ribonucleotides (54), collecting I ml fractions. 2'-Deoxyadenosine and 2'-0-methyladenosine eluted in the first 10 ml with a peak at fractions 3-8; adenosine and N"methy1adenosine bound and were eluted only after the change to lower p H with a peak in fractions 19-24.
Uric acid was determined using uricase (Sigma, Type I), creatinine with Sigma Kit 555 and protein by the method of Lowry, et al. (33) .
Patients. Patients I and 2 are sibs whose case histories have been previously reported (44) . Patient I was diagnosed prenatally as A D A deficient. T h e diagnosis was confirmed both enzymatically and by in vitro tests of immune function. H e was clinically healthy at the start of the study. T h e case history for patient 3 has also been reported (26). She was critically ill for the first 4 months of the study. Patient 4 was a 6-month-old child severely ill with multiple infections and classic manifestations of S C I D (14). Three of the control patients studied were similar to the A D A deficients in that they were either clinically critically ill o r immunodeficient (controls 1-3). T h e ages of controls (6 months to 3 years) essentially overlapped with those of the A D A deficients at the onset of study (6 wk to 2% years).
RESULTS
Analysis of fractionated urine by HPLC a n d detection of urinary ADA substrates. W e fractionated urines from A D A deficient and nonADA deficient, immunodeficient and normal children on anion exchange columns, collected and lyophilised the fraction which contains adenine nucleosides (fraction 2, see "Materials and Methods") and analyzed this fraction by HPLC. We found seven compounds in urines of ADA deficient children that absorbed UV at 260 nm and behaved as if they were substrates for ADA. Thus, all seven peaks disappeared from the chromatogram after incubation with exogenous ADA ( Figure 2B ).
Zdentrfication and quantitation of four ADA substrates known to be present in urine. Four of the seven peaks coeluted respective1 2 with I-methyladenosine, adenosine, 2'-deoxyadenosine or Nmethyladenosine and had the same 250/260 and 280/260 UV ratios as the authentic compounds. When each of the peaks was collected individually, an aliquot incubated with ADA and rechromatographed, each of the original peaks disappeared and a new peak appeared that coeluted with and had the same 250/260 and 280/260 UV ratios as the expected authentic product of deamination and which represented over 9090 recovery from the original peak (Table 1 and Fig. 2) . The first three compounds identified, I-methyladenosine, adenosine and N6-methyladenosine, have been previously detected in urine of normals (4) whereas 2'-deoxyadenosine has been found previously only in urine of ADA deficient children (9, 26, 27, 32, 36, 50).
The four ADA deficient children excreted dramatically increased amounts of 2'-deoxyadenosine, ranging from 220-1090 nmoles/mg creatinine (Table 2) , similar to previously reported values. NonADA deficient children, whether immunodeficient or healthy, excreted undetectable (<0.01 nmoles/mg creatinine) amounts of 2'-deoxyadenosine. Excretion of adenosine was also increased, although less markedly, with an average excretion of 29.4 + 5.7 compared to excretion of 4.1 f 1.0 nmoles/mg creatinine by the nonADA deficient children. Quantitation of I-methyladenosine or N6-methyladenosine excretion was complicated by the fact that the two compounds can interconvert in solution (19).
Combined 1-methyladenosine + N"methy1adenosine excretion by the ADA deficient children was only slightly increased (approximately 2-fold) when compared with excretion by the three younger children (102 f 24 versus49 + 3.6 nmoles/mg creatinine). 1-Methyladenosine excretion by both ADA deficient and nonADA deficient young children was markedly greater than N6-methyladenosine excretion. The two older, healthy children excreted markedly lower concentrations of N" + 1-methyladenosine, primarily because of markedly decreased excretion of l-methyladenosine (Table 2) . [An additional healthy 6-month-old infant also excreted 4-fold higher amounts of I-methyladenosine (40 nmoles/ mg creatinine) than did the healthy 3-year-old children, suggesting that I-methyladenosine excretion decreases with age.]
Three additional urinary ADA substrates. We found three additional compounds that behaved as if they were substrates for ADA and have not been previously described in urines of normals or of ADA deficient patients. The first two of these three compounds appeared in urine of ADA deficient patients as a double peak eluting shortly after 2'-deoxyadenosine ( Figure 2B ). The later eluting component of the double peak eluted with authentic 2'-0-methyladenosine and was degraded by ADA at concentrations similar to those required to degrade adenosine and authentic 2'-0-methyladenosine. The earlier eluting component of the double peak required higher concentrations of ADA, similar to those required for conversion of N"methyladenosine to inosine. When this double peak was collected, lyophilised and applied to an Affigel 601 boronate gel column, the presumed 2'-0-methyladenosine eluted in the void volume of the column, consistent with 2'-0-methylation of the ribose moiety and loss of cis-diol groups. The other component bound to Affigel 601 columns and was eluted by lowerkg the pH. We were, thkrefore, able to completely separate the two compounds by chromatography on Amgel 601 for further characterization.
Further characterization and quantitation of 2'-0-methyladenosine in urine of ADA deficient children. In addition to having identical retention times (as determined by coelution) and lacking vicinal hydroxyl groups, the presumed 2'-0-methyl compound shared other properties with authentic 2'-0-methyladenosine. The presumed 2'-0-methyladenosine and the compounds generated by deamination (2'-0-methylinosine) and acid hydrolysis (adenine) coeluted with and had UV spectral ratios like those of authentic 2'-0-methyladenosine and the compounds generated by deamination and acid hydrolysis of authentic 2'-0-methyladenosine (Tables 1 and 3) . We could not detect any 2'-0-methyladenosine in urines of normal or nonADA deficient, immunodeficient children. We Table 2 . Average + S.D. ' nmoles/mg creatinine: Ar, adenosine; dAr, 2'-deoxyadenosine; I Me Ar + N%e Ar, I-methyladenosine + NG-methyladenosine; 2'0 Me Ar, 2'-methyladenosine and R-Ar, R-adenosine or "Peak X . Compounds were quantitated by determining area as measured by height and width at half peak height, compared with areas of authentic compounds. For R-adenosine and R-inosine, the area/pmole obtained for adenosine and inosine was used. Quantitation of 2'0 Me Ar and R-Ar was performed by using several C18 pBondapak Columns, which either optimally separated the substrates (2'-0-methyladenosine and R-adenosine) or the deamination products (2'0-methylinosine and R-inosine) or both on the same column. Values obtained by the two separate methods of quantitation agreed within 10%. We could not ascertain why the commercially packed columns differed in resolution. We made only limited attempts to modify the conditions and were unsuccessful in obtaining resolution on all columns.
Controls: Patients I and 2 were immunodeficient, nonADA deficient infants. Patient 2 was severely ill. Patient 3 was a critically ill, nonimmunodeficient child. Patients 4 and 5 were healthy, normal children.
"eventy days following last transfusion. quantitated 2'-0-methyladenosine in urines of ADA deficient patients both by measuring the 2'-0-methyladenosine peak and by isolating the peak and measuring the deamination product. Both measurements were in good agreement. 2'-0-Methyladenosine excretion ranged between 0.7-2.2 nmoles/mg creatinine in three untreated ADA deficient natients (Table 2) . A fourth ADA deficient child excreted 3.5 nmoles/mg creatinine 70 days after a prior erythrocyte transfusion. Urine from three infants with various other immunodeficiency disorders and from two normal children were also analyzed. We could not detect 2'-0-methyladenosine excretion by any of these children with a lower limit of sensitivity ranging from <0.05 to <O. 10 nmoles/mg creatinine.
Further characterization and quantitation of compound R-adenosine. We have not as yet identified the first of the two closely eluting ADA sensitive compounds (Fig. 2 and 3) . This compound, which we have designated R-adenosine or peak " X , in contrast to 2'-0-methyladenosine, was found in urine of normals as well as in urine of ADA deficient patients. R-adenosine had 250/260 and 280/260 UV spectral ratios of 0.82 and 0.12, consistent with an adenine nucleoside, but did not comigrate with any of the 16 previously described, modified nucleosides which were tested (Table 1) .
The deamination product of R-adenosine eluted slightly after authentic 2'-0-methylinosine and separately from inosine as well as from I-methyl, 2'-deoxy, 3'-0-methyl or 5'-deoxyinosine (Table  I ). The R-inosine had 250/260 and 280/260 UVC ratios consistent with an inosine nucleoside (1.36 and 0.28). Treatment of the Rinosine with purine nucleoside phosphorylase gave rise to a compound with the retention time of hypoxathine.
We could find no evidence for modification in the 2', 3' hydroxyl portion of the ribose moiety or modification in the purine ring. Thus, R-adenosine, in contrast to 2'-0-methyladenosine, bound to Affigel 601 columns and eluted with a peak in fractions 23-30, slightly after the adenosine and N"methy1adenosine peaks in fraction 19-24. The R-adenosine was very acid labile, being completely hydrolyzed under conditions where only 18% of adenosine was hydrolyzed (0.1 N PCA for 10 min at 100°C) and only a single product could be detected under all conditions of hydrolysis. The product of acid hydrolysis coeluted with adenine and had appropriate 250/260 and 280/260 UV ratios (Table 3 and Fig. 3) . The coelution of the acid hydrolysis product with adenine indicates that the purine ring is not I-methyl, 2-methyl, N6-methyl, N6,N6-dimethyl or isopentenyl adenine, all of which had retention times different from adenine (Table I ). The compound, isolated both from normal and ADA deficient urine, was a relatively poor substrate for ADA, requiring concentrations of ADA similar to those needed to deaminate N~-methyladenosine.
We quantitated excretion of R-adenosine both by measuring the area of the peak, using columns which best separated the nucleoside from 2'-0-methyladenosine, and by measuring the area of the deamination product, using columns which best separated the deamination vroduct from 2'-0-methylinosine. The two methods were in good agreement, assuming relative extinction coefficients as for adenosine and inosine. The four ADA deficient children excreted between 4.6 and 6.9 nmoles R-adenosine/mg creatinine, compared to normal excretion of 1.4 k 0.4 (Table 2 ).-N"2'-0-Methyladenosine. The third, previously undescribed ADA sensitive urinary compound coeluted with N6,2'-O-dimethyladenosine. When this peak (isolated from both normal and ADA deficient urine) was incubated with ADA, a peak was generated that coeluted with and had the same 250/260 UV ratios as 2'-0-methylinosine, the deamination product of N6,2'-0-dimethyladenosine. This compound was identified in urine of both normals and ADA deficient patients. The presumed N6,2'-0-dimethyladenosine peak comigrated with at least one other nonADA sensitive compound and the peak has not as yet been Fig. 3 . Characterization of R-adenosine (peak X). The unknown modified adenine nucleoside (peak " X ) (Fig. 2) was collected by HPLC from urine of an ADA deficient child, bound to and eluted from a boronate column (Affigel601), concentrated and rechromatographed alone ( I ) and together with authentic 2'-0-methyladenosine (2). The "X" compound was also hydrolyzed in acid and the product rechromatographed alone (3) and together with authentic adenine (4). The large peak eluting at the void of the column is caused by the high salt content of the samples and was also obtained in buffer controls. accurately quantitated. Excretion, as determined only by the difference in the area of the peak containing N6,2'-O-dimethyladenosine before and after incubation with ADA, ranged from ~0.5-2.9 nmoles/mg creatinine with apparent overlap between ADA deficient and nonADA deficient children (data not shown).
MINUTES -
Analysis by HPLC of anion exchange fractions 1, 3 and 4 and unfractionated urine. We sought to determine if there were ADA sensitive compounds in the three remaining fractions separated by chromatography of urine on the anion exchange column. We found 1-methyladenosine in fraction 1, where the authentic 1-methyladenosine is also found (Fig. I) and this amount was included in the quantitation of total excretion (page 5, Table 2 ). No other ADA sensitive compounds were detected in any other fraction, but any alkali unstable compounds would not be detected. We also could not detect any additional ADA sensitive compounds in whole urine not pretreated by anion exchange chromatography. The multiple compounds present in whole urine could have obscured additional ADA sensitive compounds.
Effect of erythrocyte exchange transfusion on excretion of adenine nucleosides. All four children were treated by partial erythrocyte exchange transfusions (patients 1-3) or a combination of total and partial exchange transfusions (patient 4) (41) . The normal erythrocytes contain both the deficient enzyme and transport sites for nucleosides. We sought to determine if such transfusions affected excretion of 2'-0-methyladenosine and R-adenosine in the same manner that such transfusions have been reported to diminish excretion of 2'-deoxyadenosine and to a lesser extent, adenosine (36) . We arbitrarily chose urines obtained 1 month, 3 months and 2 years after the start of repeated transfusions. As has been previously reported, 2'-deoxyadenosine excretion fell dramatically after the first transfusion and was maintained at these lowered concentrations; however, they are still markedly elevated compared to normal. Adenosine excretion also diminished, although it was much less dramatic and remained higher than in normals. Excretion of R-adenosine fell rapidly in all four patients and was Table 2 . Patients 1-3 were partially exchange transfused (10-15 ml/kg) every 2-3 wk for the first year and approximately every 5 wk during the second year.
Patient 4 was totally exchange transfused as well as partially transfused.
Seventy days following last transfusion.
reduced from 4-5-fold increase to essentially normal concentrations. Excretion of 2'-0-methyladenosine decreased following transfusions, initially at a slower rate but remained detectable (Table 4) . Increasing age would not appear to be the reason for the observed diminution of excretion over the 2 year period since ADA deficient patient 2 was as old (2% years of age) before treatment as were patients I and 3 at the end of the study (2 and 2% years of age). Disease state would also not appear to be the determining factor for alterations in excretion, because ADA deficient patient 1 was clinically healthy while patient 3 remained critically ill throughout the first 3 months of the study (27). The controls similarly represented a spectrum of severely ill to clinically healthy children.
Excretion of N2-methylguanosine. We also determined the excretion of a nonadenine containing modified purine nucleoside, N2-methylguanosine. There was no apparent difference in the excretion of this nonadenine containing modified nucleoside by ADA and nonADA deficient children. Thus the ADA deficient children excreted between 15 and 30 nmoles/mg creatinine (19.8 k 0.6, n = 4) compared to excretion by nonADA deficient children which ranged from 1646 (27.3 + 13.2, n = 4).
DISCUSSION
We have found that ADA deficient patients, but not normals, excrete detectable quantities of the modified adenine nucleoside, 2'-0-methyladenosine. We have also found two additional modified adenine nucleosides not previously reported in human urine. These nucleosides are N6,2'-0-methyladenosine and an, as yet, incompletely characterized modified adenine nucleoside, R-adenosine. ADA deficient patients excrete approximately 4-fold increased amounts of this unidentified, modified adenine nucleoside. Our inability to determine if R-adenosine is modified on the purine or the ribose by the methods used suggests that either the sugar is modified on sites other than the 2',3' hydroxyls or that the modification of the purine ring is labile to the conditions of acid hydrolysis utilized. Because both normals and ADA deficient patients excreted R-adenosine, we considered that indentification of the exact modifications of R-adenosine, although of general interest, was not likely to be of major significance for ADA deficiency. Studies are in progress to further characterize this compound. We have also confirmed previous reports of massively increased excretion of 2'-deoxyadenosine (9, 28, 32, 36, 37, 50) as well as moderately (approximately 6-fold) increased excretion of adenosine by ADA deficient patients (9). Excretion of l-methyladenosine also appeared to be slighty increased. We have not found any difference in excretion of a nonadenine contained modified nucleoside (N2-methylguanosine), supporting the idea that observed differences in adenine nucleoside excretion do not reflect some nonspecific alteration in nucleoside metabolism. Consistent with the hypothesis that the increased excretion of all four adenine nucleosides results from deficiency of ADA, we have also found that the excretion of R-adenosine and 2'-0-methyladenosine as well as of adenosine and 2'-deoxyadenosine by ADA deficient patients is diminished following "enzyme replacement therapy" with partial erythrocyte exchange transfusions (36, 41) .
Modified adenine nucleosides, other than 2'-deoxyadenosine, are constituents of RNA in mammals and other eukaryotes (34, 39,47, 5 1,53) and therefore their excretion should reflect turnover of RNA. Modification of the adenine nucleoside moiety appears to occur only post-transcriptionally, after incorporation &to-RNA. It does not appear to involve direct incomration of modified adenine compb;nds into RNA. The extent and type of modification varies with the different classes of RNA. For example, N"2'-0-dimethyl compounds occur in the cap sturcture of mRNA and in low molecular weight nuclear RNA; 2'-0-methyladenosine occurs in ribosomal RNA as well as in the cap structure of mRNA and I-methyladenosine is a feature of tRNA (7, 13, 3 1, 34, 35, 39, 47,48,5 1,53). Whether modified adenine nucleosides in urine are derived from turnover of endogenous RNA, of dietary purines or
